A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

BACKGROUND: Ofranergene obadenovec (VB-111) is an anticancer viral therapy that demonstrated in a phase II study a survival benefit for patients with recurrent glioblastoma (rGBM) who were primed with VB-111 monotherapy that was continued after progression with concomitant bevacizumab. METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales: Cloughesy, Timothy F, Brenner, Andrew, de Groot, John F, Butowski, Nicholas A, Zach, Leor, Campian, Jian L, Ellingson, Benjamin M, Freedman, Laurence S, Cohen, Yael C, Lowenton-Spier, Noa, Rachmilewitz Minei, Tamar, Fain Shmueli, Shifra, Wen, Patrick Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229248/
https://www.ncbi.nlm.nih.gov/pubmed/31844890
http://dx.doi.org/10.1093/neuonc/noz232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229248/
https://www.ncbi.nlm.nih.gov/pubmed/31844890
http://dx.doi.org/10.1093/neuonc/noz232

Ejemplares similares